MedTrace Logo

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma

NCT03834012 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2019-07-17

No results posted yet for this study

Summary

Approximately 480 (120 per group) would need to complete the 6 weeks of treatments.

Conditions

Interventions

DRUG

Beclomethasone 800 µg per day

Intervention: Drug: Beclomethasone 800 µg HFA per day

DRUG

Placebo

Intervention: Drug: placebo

DRUG

Beclomethasone 400 µg per day

Intervention: Drug: Beclomethasone 400 µg HFA per day

DRUG

Beclomethasone 640 µg per day

Intervention: Drug: Beclomethasone 640 µg per day

Sponsors & Collaborators

  • Adamis Pharmaceuticals Corporation

    lead INDUSTRY

Principal Investigators

  • Dennis Carlo · CEO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-28
Primary Completion
2019-11-30
Completion
2020-04-30
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03834012 on ClinicalTrials.gov